Company intelligence / Profile preview
RJK Biopharma
Shanghai, Shanghai Shi, Chinarjkbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
RJK Biopharma is a Shanghai-based biotech company developing biological products and AAV-based gene therapies targeting neurodegenerative diseases. Its lead program, RJK‑002 for ALS, has reached Phase 1 clinical trials as of November 2023. The company is recognized for its work on protein phase separation as a novel therapeutic approach to neurological disorders.
- Therapeutic areas
- CardiovascularOphthalmologyNeurology
- Modalities
- Biological productsAAV based gene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
None publicly disclosed
Beyond the preview
Go deeper on RJK Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RJK Biopharma.